Natco Pharma Declares ₹1.50 Interim Dividend, Eyes ₹2000 Cr Fundraising
Natco Pharma declared an interim dividend of ₹1.50 per share for FY27. The company is exploring fundraising up to ₹2000 Crores. The 43rd AGM notice was approved. For Q1FY27, consolidated revenue was ₹794.4 Cr (down from ₹1,390.6 Cr) and profit was ₹206.5 Cr (down from ₹480.3 Cr).
The declaration of an interim dividend and the exploration of a significant fundraising exercise are material events. However, the reported decline in quarterly results tempers the immediate positive impact.
While the company declared an interim dividend and is exploring fundraising, the reported financial results for the quarter show a significant decrease in revenue and profit compared to the previous year, leading to a neutral sentiment.
Natco Pharma Limited announced the outcome of its Board Meeting held on August 14, 2026. The Board approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, along with the Limited Review Report from the Statutory Auditors.
An interim dividend of ₹1.50 per equity share (75%) for the financial year 2026-27 was declared. The record date for this dividend has been fixed as August 20, 2026, with the payment commencing on August 26, 2026.
The company is also exploring the possibility of raising funds up to ₹2000 Crores through various methods, including equity shares or other securities, subject to necessary approvals.
Furthermore, the Board approved the Notice for the 43rd Annual General Meeting (AGM) for the Financial Year 2025-2026, with the Chairman and Managing Director authorized to fix the date and time for the meeting, which will be conducted via Video Conference (VC) / other Audio Visual Means (OAVM).
The Reconstitution of the Risk Management Committee and the Environment, Social and Governance Committee was also approved, effective August 14, 2026. Details of these committees will be available on the company's website.
For the first quarter of FY27, Natco Pharma reported consolidated total revenue of ₹794.4 Crores, a decrease from ₹1,390.6 Crores in the corresponding quarter last year. The net profit for the period was ₹206.5 Crores, down from ₹480.3 Crores in the prior year. This decline is attributed to lower Lenalidomide revenue, partially offset by growth in the base business. The company's share of profit from associate Adcock Ingram Holdings Limited was ₹84.3 Crores, following NATCO's acquisition of an additional 13.25% stake in July 2026, increasing its total holding to 49%.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.